Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO) in renal cell carcinoma patients with bone metastases

Trial Profile

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO) in renal cell carcinoma patients with bone metastases

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms EIFFEL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Nov 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Oct 2020.
    • 07 Nov 2016 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top